Analysts' Recent Ratings Changes for Surface Oncology (SURF)
A number of firms have modified their ratings and price targets on shares of Surface Oncology (NASDAQ: SURF) recently: 3/7/2022 – Surface Oncology was downgraded by analysts at TheStreet from a “c-” rating to a “d” rating. 3/4/2022 – Surface Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a […]